Form 4: Amylyx Pharmaceuticals Co-CEO Exercises Stock Options
SEC Form 4 Filing
Joshua B. Cohen, Co-CEO of Amylyx Pharmaceuticals, exercised stock options and acquired 1,857 shares of common stock at a price of $1.57 on September 23, 2024.
Summary
- On September 23, 2024, Joshua B. Cohen, Co-Chief Executive Officer of Amylyx Pharmaceuticals, exercised stock options.
- This transaction resulted in the acquisition of 1,857 shares of Amylyx Pharmaceuticals' common stock at a price of $1.57 per share.
- Following the transaction, Cohen directly owns 3,239,158 shares of common stock.
- The exercised stock options were fully vested and exercisable.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction, but the exercise of options by a Co-CEO can be interpreted as a sign of confidence.
Positives
- The exercise of stock options by a Co-CEO could be seen as a positive signal, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings to gain insights into management's perspective on the company's stock.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence from the Co-CEO.
Key Dates
| Date | Description |
|---|---|
| 09/23/2024 | Date of the stock option exercise and acquisition of common stock. |
| 09/25/2024 | Date of signature for the Form 4 filing. |
| 02/26/2025 | Expiration date of the stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.